As Spark Therapeutics Chief Executive Officer, Ron Philip leads a team of talented individuals working together to develop new therapies for people living with genetic diseases. Since joining Spark in 2017, he has played a key role in Spark’s rapid growth and achievements — most notably, directing the commercial launch of Spark’s first approved gene therapy, LUXTURNA® (voretigene neparvovec-rzyl).

Ron previously served as Chief Operating Officer, where he was responsible for leading product strategy development and execution for Spark’s early and late-stage pipeline assets, including the governance and proactive management necessary to bring more gene therapies to patients living with genetic diseases. He also was responsible for the other functions, including commercial development, marketing, pricing and reimbursement, government affairs, program and alliance management, commercial operations, diagnostics, market access and patient services functions.

Before becoming COO, Ron served as Spark’s Chief Commercial Officer and Senior Vice President, Head of Global Commercial.

With more than 30 years of experience across biopharma companies and management consulting, Ron has a proven track record of improving operating performance in multiple therapeutic categories and global markets. He held several senior leadership roles at Pfizer, including Regional President for Africa/Middle East, Head of Global Business Unit Strategy, Head of Business Development Search and Evaluation and Commercial Development Lead within Pfizer’s Innovative Products Business. He also worked at Wyeth Pharmaceuticals in U.S. commercial operations, with Deloitte Consulting in their strategy and operations practice, and at Merck and Co. in the manufacturing and marketing divisions.

Ron currently serves as the Trustee and Chair of the Science Committee at the Academy of Natural Sciences of Drexel University in Philadelphia and previously was an active board member of Cure Duchenne. Ron is a graduate of Drexel University.